XML 25 R6.htm IDEA: XBRL DOCUMENT v3.19.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 12 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Cash flows from operating activities    
Net loss $ (27,131,908) $ (10,187,863)
Adjustments to reconcile net loss to cash used in operating activities    
Depreciation, amortization and accretion 2,727,067 2,591,270
Impairment of intangible assets 0 1,856,020
Stock-based compensation expense 1,022,202 596,934
(Loss) / gain from cahnge in fair value of contingent consideration 9,830,550 (6,277,873)
Warrants issuance and amendments 0 183,920
Issuance of common stock to employee 11,690 0
Derivative income (80,779) (3,983,921)
Changes in operating assets and liabilities:    
(Increase) in accounts receivable (1,162,005) (50,743)
(Increase) decrease in inventory (101,096) (26,752)
(Increase) in prepaid expenses and other (517,772) (129,249)
Increase / (decrease) in accounts payable and other 134,775 (109,707)
Increase (decrease) in accrued liabilities 961,858 (596,654)
Increase in accrued compensation 308,824 200,970
Increase in interest payable - related party 166,667 0
(Decrease) in deferred rent (1,450) (6,674)
Net cash used in operating activities (13,831,377) (15,940,322)
Cash flows used in investing activities    
Deposits 2,888 (2,200)
Purchases of fixed assets (59,848) (74,707)
Contingent consideration payment (505,025) (7,385)
Purchase of assets (500,000) (400,000)
Net cash used in investing activities (1,061,985) (484,292)
Cash flows from financing activities    
Issuance of preferred, common stock and warrants 15,180,000 11,839,995
Issuance costs related to preferred, common stock and warrants (1,479,964) (1,402,831)
Issuance of preferred, common stock and warrant 0 12,900,020
Issuance costs related to preferred, common stock and warrant 0 (1,294,235)
Warrant exercises 375,026 677,100
S-3 registered offering cost 0 (60,450)
Proceeds of debt - related party 5,000,000 0
Net cash provided by financing activities 19,075,062 22,659,599
Net change in cash, cash equivalents and restricted cash 4,181,700 6,234,985
Cash, cash equivalents and restricted cash at beginning of period 7,112,527 877,542
Cash, cash equivalents and restricted cash at end of period 11,294,227 7,112,527
Warrants issued to investors and underwriters (see Note 13) 1,888,652 4,117,997
Warrant exercise of derivative warrants 0 40,096
Contingent consideration included in accounts payable 42,821 8,980
Earn-out payment to Nuelle Shareholders 0 250,000
Purchase of asset included in contingent consideration 0 293,216
Contingent consideration related to product acquisition (Note 4) 8,833,219 2,553,169
Issuance of preferred stock related to purchase of asset 519,600 0
Conversion of debt to equity $ 5,166,667 $ 0